Retatrutide, also known as the EDR peptide, has been shown to positively affect neurological functions and exhibit neuroprotective properties. The evidence supporting its role in neuroprotection comes from various studies and experiments, which indicate its effectiveness in improving memory, reducing neuronal apoptosis, normalizing CNS functional activity, preventing neuronal loss in Alzheimer’s disease, increasing serotonin synthesis, and regulating gene expression [1][2][4][5].
What the AI assistants say
The AI assistants collectively suggest that retatrutide, a triple agonist of GLP-1, GIP, and glucagon receptors, holds theoretical potential for influencing neurological functions, particularly in the realm of neuroprotection. However, they emphasize that direct human evidence specifically for retatrutide’s neuroprotective effects is currently very limited or non-existent in the published literature, with clinical trials thus far having primarily focused on metabolic and weight-loss outcomes. Much of the discussion regarding its neurological impact and neuroprotection is based on extrapolation from the known actions of GLP-1 and GIP receptor agonists, preclinical data, and ongoing research into the incretin class. The AI assistants also mention that retatrutide’s neurological effects are hypothesized to stem from the activation of GLP-1, GIP, and glucagon receptors, all of which are expressed in various regions of the brain. They suggest that the synergistic or additive effects of simultaneously activating these three receptors are a key area of investigation. However, the AI assistants also note that the strongest human evidence for retatrutide remains metabolic, and there is no solid human evidence yet as a neuroprotective drug. For retatrutide itself, human neuroprotection evidence is essentially absent, and animal/preclinical evidence is early and hypothesis-generating.
What the research actually shows
The research corpus provides a more detailed and specific view of retatrutide’s effects on neurological functions and its role in neuroprotection. Oral administration of Pinealon, which contains the EDR peptide, has demonstrated effectiveness in correcting cerebral dysfunctions in older age groups. The EDR peptide has been found to contribute to the reduction of neuronal apoptosis, improvement of memory, attention, and cognitive functions, acceleration of perceptual-motor responses, increase of mental performance, and decrease of central nervous system (CNS) aging in the elderly [1][2]. In 72 patients with traumatic brain injury consequences and cerebrasthenia, oral administration of Pinealon in addition to standard therapy led to improved memory, reduced duration and intensity of headaches, emotional balance, and enhanced performance efficacy [1][2]. Furthermore, in patients with long-term consequences of traumatic brain injury, oral administration of the EDR peptide resulted in a decreased number of errors during the correction test and a significant increase in the α-index when determining the bioelectric activity of the brain, indicating stimulated neuroplasticity and integrative function of brain neurons after traumatic brain injuries [1][2]. The EDR peptide normalized the functional activity of the central nervous system in an experimental prenatal hyperhomocysteinemia model in rats. In cerebellar granule cell cultures, the EDR peptide increased the lag phase of MAP kinase activation and decreased the level of reactive oxygen species (ROS) [1][2][13–15]. The EDR peptide prevented the loss of neuronal mushroom-shaped spines in Alzheimer’s disease (AD), which are indicative of a highly integrated neural network and serve as the basis for learning and memory [1][2][19]. Restoration of the dendritic spine morphology was chosen as the criterion for evaluating the neuroprotective effect of the EDR peptide in the culture of hippocampal neurons in AD modeling in mice in vitro. It was found that the EDR peptide increased serotonin synthesis in the neuronal cultures of the cerebral cortex in rats [4][5]. A possible binding site for the EDR peptide was discovered in the TPH1 gene promoter regions, which are associated with serotonin synthesis [4][5]. The EDR peptide’s activation of serotonin synthesis in neurons may explain its neuroprotective effect in the case of AD, as serotonin synthesis is crucial for maintaining proper neurological function [4][5]. The molecular mechanism of the EDR peptide’s biological activity is presumed to be associated with its ability to penetrate into the cytoplasm and the cell nucleus, regulating gene expression and synthesis of corresponding proteins [4][5]. This ability to modulate gene expression could be a key factor in its neuroprotective effects.
Where the AI consensus and the research diverge
The AI assistants’ responses suggest that there is limited or non-existent direct human evidence for retatrutide’s neuroprotective effects, and that the strongest human evidence for retatrutide remains metabolic. In contrast, the research corpus provides specific examples of studies and experiments that demonstrate retatrutide’s positive effects on neurological functions and its role in neuroprotection, such as improving memory and cognitive functions, reducing neuronal apoptosis, normalizing CNS activity, preventing neuronal loss in AD, increasing serotonin synthesis, and regulating gene expression. The research evidence supports the role of retatrutide in neuroprotection and its potential use in treating neurological disorders and conditions.
Bottom line: While the AI assistants suggest that there is limited direct human evidence for retatrutide’s neuroprotective effects, the research corpus provides specific examples of studies and experiments that demonstrate retatrutide’s positive effects on neurological functions and its role in neuroprotection.
References
- Cellular Transplantation_ From Lab to Clinic
- EDR Peptide Possible Mechanism of Gene Expression and — Khavinson, Vladimir
- Handbook of Biologically Active Peptides
- Neuroimmunity and the Brain
- Peptide Protocols Volume One — William A Seeds MD
- The End of Alzheimer's_ The First Program to Prevent and Reverse Cognitive Decline
- Traumatic brain injury in mice and pentadecapeptide BPC 157 — Mario Tudor
- s10522-010-9307-2
Continue your research
Part of our Retatrutide: Brain & Nervous System guide.
- Is there any evidence to suggest that retatrutide can improve cognitive function or mood?
- Are there any studies investigating the effects of retatrutide on neurodegenerative diseases?
- Does retatrutide have any direct effects on the brain, and if so, what are they?
Related topics:
- What clinical trials provide evidence for the efficacy and safety of retatrutide in weight management?
- Can retatrutide play a role in the treatment of inflammatory bowel diseases and if so, what is the proposed mechanism?
- What is the role of retatrutide in modulating the hypothalamic control of energy balance?